{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:04:44Z","timestamp":1789160684342,"version":"build-2803163510"},"reference-count":30,"publisher":"SLACK, Inc.","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Refract Surg"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To characterize postoperative visual symptoms and optic clarity issues across intraocular lens (IOL) types, reported in U.S. Food and Drug Administration (FDA) device reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective observational analysis of FDA Manufacturer and User Facility Device Experience (MAUDE) reports on visual symptoms and\/or IOL optic clarity issues, from January 1, 2016 through December 31, 2025. Structured MAUDE fields served as the primary data source, with report narratives analyzed using automated natural language processing to supplement classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 17,204 postoperative MAUDE reports met inclusion criteria (16,198 with visual symptoms and 2,510 with clarity issues; both present in 1,504 reports). Multifocal and extended depth of focus (EDOF) IOLs showed a higher proportion reporting of visual symptoms than monofocal IOLs (97.5%, and 98.6% vs 85.5%, respectively,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) and specifically glare (21.8% and 24.8% vs 8.6%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) and halos (29.7% and 30.1% vs 8.6%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). Clarity issues were reported more frequently in monofocal IOLs than in multifocal and EDOF IOLs (27.8% vs 11.0% and 8.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). Overall, clarity issues were reported later than visual symptoms (64.9 \u00b1 72.6 vs 7.9 \u00b1 20.9 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001), and visual symptoms more often required IOL exchange than clarity issues (62.9% vs 20.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In MAUDE postoperative reports, multifocal and EDOF IOLs had a higher proportion of visual symptoms and specifically glare and halos, whereas monofocal IOLs had a higher proportion of later reported clarity issues. These findings reflect differences in reported events rather than population-level risk and may inform post-market surveillance priorities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3928\/1081597x-20260701-01","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:15:11Z","timestamp":1788970511000},"source":"Crossref","is-referenced-by-count":1,"title":["Visual Symptoms and Optic Clarity Disturbances Associated With Intraocular Lenses in U.S. Food and Drug Administration Device Reports"],"prefix":"10.3928","volume":"42","author":[{"given":"Idan","family":"Hecht","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota;"},{"name":"Helsinki Retina Research Group, University of Helsinki, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruti","family":"Sella","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kanclerz","sequence":"additional","affiliation":[{"name":"Helsinki Retina Research Group, University of Helsinki, Helsinki, Finland;"},{"name":"Hygeia Clinic, Gda\u0144sk, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimo","family":"Tuuminen","sequence":"additional","affiliation":[{"name":"Helsinki Retina Research Group, University of Helsinki, Helsinki, Finland;"},{"name":"Department of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2022.101150"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.10.001"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/life13010053"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.03.017"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000719"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0626-RA"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2009.01.031"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.jcrs.0000000000001908"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000296"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.17560"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.08.009"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/20552076251314094"},{"key":"e_1_3_2_14_2","unstructured":"U.S. Food and Drug Administration. About manufacturer and user facility device experience (MAUDE) database. Updated December 8 2025. Accessed February 5 2026. https:\/\/www.fda.gov\/medical-devices\/mandatory-reporting-requirements-manufacturers-importers-and-device-user-facilities\/about-manufacturer-and-user-facility-device-experience-maude-database"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105591"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/24741264241264356"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogla.2020.12.012"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.jcrs.0000000000000739"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.5334\/egems.221"},{"key":"e_1_3_2_20_2","unstructured":"Electronic Code of Federal Regulations. 21 CFR Part 803: medical device reporting. Updated February 2 2026. Accessed February 5 2026. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-H\/part-803"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S282469"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joco.2018.04.003"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2010.06.003"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S44208"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-017-0509-0"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2019.03.005"},{"key":"e_1_3_2_27_2","unstructured":"Bethke W. The 2026 IOL preferences Survey. Review of Ophthalmology. 2026;January:33\u20136. https:\/\/www.reviewofophthalmology.com\/article\/the-2026-iol-preferences-survey"},{"key":"e_1_3_2_28_2","volume-title":"Ophthalmic market trends: US cataract edition, Q2 2025","author":"Market Scope","year":"2025","unstructured":"Market Scope. Ophthalmic market trends: US cataract edition, Q2 2025. Market Scope, LLC; 2025. Accessed February 11, 2026. https:\/\/www.market-scope.com\/pages\/reports\/521\/ophthalmic-market-trends-us-cataract-edition-q2-2025"},{"key":"e_1_3_2_29_2","unstructured":"Alcon Laboratories Inc. Alcon strengthens leadership in IOL innovation with launch of Clareon Portfolio in the U.S. March 7 2022. Accessed February 21 2026. https:\/\/www.alcon.com\/media-release\/alcon-strengthens-leadership-iol-innovation-launch-clareon-portfolio-us"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.1597"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.jcrs.0000000000000827"}],"container-title":["Journal of Refractive Surgery"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:15:21Z","timestamp":1788970521000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/1081597X-20260701-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["10.3928\/1081597X-20260701-01"],"URL":"https:\/\/doi.org\/10.3928\/1081597x-20260701-01","relation":{},"ISSN":["1081-597X"],"issn-type":[{"value":"1081-597X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}